Biomarkers Enabling Diabetes and Obesity Management

  • ID: 4188689
  • Report
  • Region: Global
  • 68 Pages
  • Frost & Sullivan
1 of 3
Novel Biomarker Research is Likely to Transform the Future of Obesity and Diabetes Management

Obesity and diabetes are areas of growing concern across both, developed and developing countries. The rising geriatric population is likely to contribute to an increased prevalence of obesity and diabetes across the global landscape. Biomarker research is likely to facilitate the emergence of novel tools that may be useful for enhanced management of obesity, diabetes and related complications in the near future.

There are several biomarkers that are currently being studied for predicting the risk and progression of several diseases such as type 2 diabetes, diabetic kidney disease, obesity and related disorders. Furthermore, companies are looking to leverage new biomarker-based platforms for early diagnosis and timely clinical management of obesity, diabetes and related complications. Biomarker-based research may also open novel paradigms for drug discovery and development obesity and diabetes disorders.

Note: Product cover images may vary from those shown
2 of 3
1. Executive Summary
1.1 Scope of Research
1.2 Research Methodology
1.3 Key Findings

2. Role of Biomarkers in Diabetes and Obesity Management
2.1 Diabetes and Obesity Disorders Contribute to Global Mortality
2.2 Biomarker Platforms Lead Diverse Clinical and Research Applications
2.3 Metabolomic and Proteomic Biomarker Assays Dominate the Technology Landscape

3. Impact Analysis and Assessment
3.1 Summary of Key Industry Drivers and Restraints
3.2 Industry Growth Likely to Be Fueled by Rising Demand for Personalized Medicine
3.3 Biomarker Validation Likely to Limit Industry Growth
3.4 Summary of Key Technology Drivers and Restraints
3.5 Rapid Technological Advances are Likely to Drive the Growth of Novel Biomarker Platforms
3.6 False Positive Results across Biomarker Studies are a Major Setback

4. Basic Research Applications
4.1 Biomarker Research Fuels Novel Scientific Discoveries
4.2 Steady Growth in Biomarker Research Publications
4.3 Significant Research Funding for Diabetes Biomarkers
4.4 Metabolomic Biomarkers Likely to Emerge across Type 2 Diabetes and Obesity
4.5 Metabolomic Biomarkers Likely to Emerge across Diabetes and Related Complications

5. Diagnostic Applications
5.1 Exploring Novel Diagnostic Biomarkers for Diabetes
5.2 Novel Metabolomic Biomarker Panel for Diabetes
5.3 Comprehensive Biomarker Testing Services Platform
5.4 New Prognostic Biomarker for Diabetic Nephropathy
5.5 Novel Assay for Diabetic Kidney Disease
5.6 Advanced Glycation End Products as Diagnostic Biomarkers
5.7 Novel Metabolomic Biomarker Profiling Platform

6. Drug Discovery and Development Applications
6.1 Obesity and Diabetes Biomarker Discoveries are Likely to Fuel Novel Therapies
6.2 Ongoing Late Phase Clinical Studies are Indicative of the Emerging Potential of Diabetes and Obesity Biomarkers
6.3 Biomarkers Likely to Play a Larger Role in Diabetes Management
6.4 Companion Diagnostic Platform for Obesity Treatment
6.5 Novel Companion Diagnostic Platform for Diabetes Management

7. Strategic Insights and Future Perspectives
7.1 Research and Development Partnerships Dominate the Collaborative Landscape
7.2 Key Research and Development Partnerships
7.3 Key Collaborations for Service Platforms, Product Licensing, and Commercialization
7.4 North America Dominates the Regional Landscape for Biomarker Technologies across Diabetes and Obesity Indications
7.5 Technology Roadmap

8. Overview of the Patent Landscape
8.1 Patent Research Scope and Concepts
8.2 Patent Applications for Diabetes and Obesity Biomarkers Likely to Increase in the Future
8.3 US Leads the Global Patent Landscape for Diabetes and Obesity Biomarkers
8.4 Life Science Companies Dominate the Patent Landscape

9. Growth Opportunities and Companies to Action
9.1 Growth Opportunity 1: Point-of-Care Diagnostics
9.2 Growth Opportunity 2: Personalized Medicine
9.3 Growth Opportunity 2: Patient Risk Stratification
9.4 Strategic Imperatives for Success and Growth

10. Appendix
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll